← Back to Search

Glucan Synthase Inhibitor

Ibrexafungerp for Histoplasmosis (FURI Trial)

Phase 3
Waitlist Available
Research Sponsored by Scynexis, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 42, day 84
Awards & highlights
No Placebo-Only Group
Pivotal Trial

Summary

This trial tests ibrexafungerp, a new medication for adults with severe fungal infections who haven't responded to other treatments. It works by breaking down the fungus's cell walls, helping to stop the infection.

Eligible Conditions
  • Histoplasmosis
  • Invasive Pulmonary Aspergillosis
  • North American Blastomycosis
  • Yeast infection
  • Coccidioidomycosis
  • ABPA
  • Invasive Candidiasis
  • Valley Fever
  • Oral Thrush
  • Blastomycosis
  • Chronic Pulmonary Aspergillosis
  • Emerging Fungal Infections

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 42, day 84
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 42, day 84 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Assessment of Global Response
Secondary study objectives
Assessment of Recurrence of Baseline Fungal Infection
Assessment of survival

Side effects data

From 2019 Phase 3 trial • 376 Patients • NCT03734991
26%
Diarrhoea
16%
Nausea
9%
Headache
7%
Abdominal pain
6%
Abdominal discomfort
5%
Bacterial vaginosis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Ibrexafungerp (SCY-078)
Placebo

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Ibrexafungerp (SCY-078)Experimental Treatment1 Intervention
Ibrexafungerp (SCY-078), orally administered QD for up to 180 days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ibrexafungerp
2019
Completed Phase 3
~1220

Find a Location

Who is running the clinical trial?

Scynexis, Inc.Lead Sponsor
17 Previous Clinical Trials
2,245 Total Patients Enrolled
David Angulo, MDStudy DirectorSponsor GmbH
7 Previous Clinical Trials
957 Total Patients Enrolled
~27 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top